NAD+ (Nicotinamide Adenine Dinucleotide) 10% 30 mL Pump
Nicotinamide Adenine Dinucleotide (NAD+) is a universal cellular electron transporter, coenzyme, and signaling molecule present in all cells of the body and is essential for cell function and viability. Along with NAD+, its reduced (NADH) and phosphorylated forms (NADP+ and NADPH) are also important. NAD+ and its redox partner NADH are vital for energy (ATP) production in all parts of cellular respiration: glycolysis in the cytoplasm and the Krebs cycle and electron transport chain in the mitochondria.
NADP+ and NADPH tend to be used in anabolic reactions, including biosynthesis of cholesterol and nucleic acids, elongation of fatty acids, and regeneration of glutathione, a key antioxidant in the body. In other cellular processes, NAD+ and its other forms are used as substrates by NAD+-dependent/-consuming enzymes to make post-translational modifications to proteins. NAD+ also serves as a precursor for the secondary messenger molecule cyclic ADP ribose, which is important for calcium signaling.
NAD+ is naturally synthesized de novo in the body from the amino acid tryptophan or vitamin precursors, nicotinic acid and nicotinamide, collectively known as vitamin B3 or niacin; it can also be synthesized from biosynthetic intermediates, including nicotinamide mononucleotide and nicotinamide riboside. Within salvage pathways, NAD+ is continuously recycled within cells being interconverted to and from its other forms.3 Cell culture studies also suggest that mammalian cells can take up extracellular NAD+.
NAD+ levels are highest in newborns and steadily decline with increasing chronological age. After age 50, they are approximately half of the levels seen in younger adults. The question of why NAD+ levels decline with age has been investigated in model organisms. During redox reactions NAD+ and NADH are not consumed but continuously recycled; however, during other metabolic processes, NAD+ is consumed by NAD+-dependent enzymes and thus could become depleted over time, contributing to increased DNA damage, age-related conditions and diseases, and mitochondrial dysfunction. Age-related decline in mitochondrial health and function is prominent in theories of aging and senescence, and studies of NAD+ depletion and subsequent oxidative damage and stress support these ideas.
A 2016 study in mice, which present age-related declines in NAD+ levels similar to those observed in humans, revealed that the age-related decline in NAD+ levels is driven by increasing levels of CD38, a membrane-bound NADase that breaks down both NAD+ and its precursor nicotinamide mononucleotide. The study also confirmed elevated CD38 gene expression in human adipose tissue from older adults (mean age, 61 years) relative to younger adults (mean age, 34 years). However, other studies in mice have demonstrated that inflammation and oxidative stress caused by aging reduce NAD+ biosynthesis. Thus, it is likely that a combination of mechanisms contribute to age-related decline of NAD+ in humans.
The clinical importance of maintaining NAD+ levels was established in the early 1900s, when it was discovered that the disease pellagra, which is characterized by diarrhea, dermatitis, dementia, and death, could be cured with foods containing NAD+ precursors, in particular vitamin B3. Notably, in contrast to vitamin B3 (niacin) supplementation, which causes the skin to flush, this side effect has not been observed with NAD+ injection. In recent years, low NAD+ levels have been linked to a number of age-related conditions and illnesses associated with increased oxidative/free radical damage, including diabetes, heart disease, vascular dysfunction, ischemic brain injury, Alzheimer’s disease, and vision loss.
IV infusion of NAD+ has been used extensively for the treatment of addiction, stemming from a study a 1961 report by Paul O’Hollaren, MD, of Shadel Hospital in Seattle, Washington. Dr. O’Hollaren described the successful use of IV-infused NAD+ for the prevention, alleviation, or treatment of acute and chronic symptoms of addiction to a variety of substances, including alcohol, heroin, opium extract, morphine, dihydromorphine, meperidine, codeine, cocaine, amphetamines, barbiturates, and tranquilizers, in over 100 cases. However, no clinical trials to date have evaluated the safety and efficacy of NAD+ treatment in addiction.
NAD+-replacement therapy may promote mitochondrial health and homeostasis, genome stability, neuroprotection, healthy aging, and longevity and may aid in treating addiction. Clinical trials evaluating these effects in humans treated with NAD+ injection have not yet been published; however, numerous clinical trials evaluating the efficacy and safety of NAD+-replacement therapy or augmentation in the context of human disease and aging have recently been completed, and many others are ongoing.
The exact mechanisms of NAD+ restoration or augmentation for potential health benefits, such as supporting healthy aging and treating age-related conditions, metabolic and mitochondrial diseases, and addiction, are unknown.
NAD+ replacement may counterbalance age-related degradation of NAD+ and its precursor nicotinamide mononucleotide by NADases, in particular CD38, thereby preventing mitochondrial dysfunction and maintaining metabolic function/energy (ATP) production. However, studies in animal models and humans (and/or samples and cell lines) indicate that NAD+ replacement supports several other biological pathways via NAD+-dependent enzymes.
There are several notable NAD+-dependent enzymes. Poly-ADP ribose polymerases (PARP 1-17) control DNA repair and nuclear stability.13 CD38 and CD157 are NADases whose products (cADP-ribose, ADP-ribose and nicotinic acid adenine dinucleotide) are used in Ca2+ signaling and intercellular immune communication. Sirtuins (Sirt 1-7) are a family of histone deacetylases that regulate of several proteins associated with cellular metabolism, cellular stress responses, circadian rhythms, and endocrine functions; Sirts have also been linked to longevity in model organisms and protective effects in cardiac and neuronal models. Sterile Alpha and Toll/Interleukin-1 Receptor motif-containing 1 (SARM1), is a recently discovered NAD+ hydrolase involved in neuronal degeneration and regeneration.
Some insight into the mechanism of action of NAD+ replacement has been obtained from studies of progeroid (premature aging) syndromes, which mimic the clinical and molecular features of aging. Werner syndrome (WS) is believed to most closely resemble natural aging and is characterized by extensive metabolic dysfunction, dyslipidemia, premature atherosclerosis, and insulin-resistant diabetes. WS is caused by mutations in the gene encoding the Werner (WRN) DNA helicase, which regulates transcription of a key NAD+ biosynthetic enzyme called nicotinamide nucleotide adenylyltransferase 1.
A 2019 study found that NAD+ depletion is a major driver of the metabolic dysfunction in WS through dysregulation of mitochondrial homeostasis. Cells with depleted NAD+ from samples of WS patients and WS animal models showed impaired mitophagy (selective degradation of defective mitochondria). NAD+ repletion restored NAD+ metabolic profiles, improved fat metabolism, reduced mitochondrial oxidative stress, and improved mitochondrial quality by restoring normal mitophagy in human cells with mutated WRN. In animal models, NAD+ repletion significantly extended lifespan and delayed accelerated aging, including increased numbers of proliferating stem cells in the germ line. Replacement of NAD+ by administering various NAD+ precursor molecules recapitulated the results, confirming that the beneficial effects are due to NAD+ repletion.
Providing additional support for the role of NAD+ in promoting mitochondrial and metabolic health, murine cells overexpressing the NADase CD38 consumed less oxygen, had increased lactate levels, and possessed irregular mitochondria, including features such as lost or swollen cristae. Isolated mitochondria from these cells showed severe loss of NAD+ and NADH compared to controls. In mice lacking CD38, NAD+ levels, mitochondrial respiratory rates, and metabolic functions were preserved during aging.
One pharmacokinetic study has evaluated changes in concentrations of NAD+ and its metabolites in a cohort of healthy male participants (n=11; NAD+ n=8 and control n=3) during NAD+ IV infusion. Participants received a 6-hour continuous IV infusion of NAD+ (750 mg dose at 3 μmoles/min), which resulted in a significant increases in plasma levels of NAD+ (398%), nicotinamide (409%), adenosine phosphoribose (ADPR; 393%) at the end of infusion relative to baseline (p <.0001); these levels were all significantly different than in the control group (p <.001, p<.001, and p<.0001, respectively). After 8 hours, differences between the groups remained significant for levels of NAD+ but not of nicotinamide and ADPR. Within both groups, levels of these two NAD+ metabolites were significantly correlated over the 8-hour timeframe (=1.0, p <.001), suggesting cleavage of NAD+ to nicotinamide and ADPR by NADases, such as CD38.
Consistent with increased nicotinamide, plasma levels of its metabolites methylnicotinamide (350%) and nicotinamide mononucleotide (NMN; 472%) also significantly increased at the end of the NAD+ infusion relative to baseline (p <.0001 and p <.05) and the control group (p <.0001 and p <.05, respectively).
In the NAD+ group, levels of NAD+ excreted in the urine significantly increased (538%) after infusion (at 6 h) relative to that measured at 30 minutes (p<.001); it was also significantly different from the controls (p <.05). This level decreased by 43% at the 8-hour time point relative to the peak at 6 hours (p <.05).
Excess NAD+ and its metabolites are excreted in urine. Urine excretion levels of nicotinamide did not change over the 8-hour period in the NAD+ group; however, those of methylnicotinamide significantly increased (403%) after infusion (at 6 h) relative to that measured at 30 minutes (p <.01). This level also decreased by 43% at the 8-hour time point relative to the peak at 6 hours (p <.05).
Notably, no significant increases in plasma or urine levels of NAD+ or its metabolites were observed within the first 2 hours of infusion, indicating rapid and complete tissue uptake and/or metabolism (at least for the first 2 hours).
Intracellular concentrations of NAD+ are maintained between 0.2 and 0.5 mM, and intracellular NAD+ pools are believed to be compartmentalized among the nucleus, cytosol, and mitochondria with NAD+ salvage pathways functioning according to compartment-specific needs. However, it is currently unknown how NAD+ injections affect intracellular and compartmental NAD+ pools.
At the time of writing, there were no other reported contraindications/precautions for NAD+ injection. Individuals with known allergy to NAD+ injection should not use this product.
The safety of NAD+ injection has not been evaluated in pregnant women. Due to this lack of safety data, pregnant women should avoid NAD+ injection.
The safety of NAD+ injection has not been evaluated in women who are breast feeding or children. Due to this lack of safety data, women who are breast feeding and children should avoid NAD+ injection.
NAD+ injection appears to be safe and well tolerated. Adverse reactions and side effects of NAD+ injection may include but are not limited to headache, shortness of breath, constipation, increased plasma bilirubin, and decreased levels of gamma glutamyl transferase, lactate dehydrogenase, and aspartate aminotransferase.
Case reports of the use of NAD+ for treatment of drug addiction provided preliminary details on adverse reactions and safety. A 1961 report described “no distress” in patients with addiction who received NAD+ using a slow IV drip rate (no more than 35 drops per minute); with a faster drip rate, patients reported headache and shortness of breath. In this report, the dosage was 500 – 1000 mg daily for 4 days followed by injections twice weekly for one month and a maintenance dose of one injection twice monthly. In one of the two cases, the patient reported constipation while on treatment.
In a 2019 study, the safety of IV infusion of NAD+ was assessed in a cohort of healthy male participants (n=11; NAD+ n = 8 and Control n = 3) aged 30-55 years using liver function tests (serum, total bilirubin, alkaline phosphatase, alanine aminotransferase, gamma glutamyl transferase, lactate dehydrogenase, and aspartate aminotransferase) and clinical observation of any adverse events. No adverse events were observed during the 6 hours infusion in either the NAD+ or placebo (saline) cohorts. In the NAD+ group, significant decreases in liver function enzymes (gamma glutamyl transferase, lactate dehydrogenase, and aspartate aminotransferase) and a significant increase in plasma bilirubin were observed at 8 hours after initiation of the NAD+ infusion. However, the changes were not considered clinically significant. The authors acknowledge the small sample sizes, especially for the control group; therefore, these results should be interpreted with caution.
Store this medication in a refrigerator between 36°F to 46°F (2°C – 8°C). Do not freeze. Protect from light. Keep all medicine out of the reach of children. Throw away any medicine after the beyond use date. Do not flush unused medications or pour down a sink or drain.
You can order NAD+ Cream from MediLab’s compounding pharmacy in the following Florida regions:
||West Palm Beach
||Port St. Lucie
|Fort Walton Beach